Tempest Therapeutics, Inc. (0001544227)... - Mar 30

The Big Picture

Tempest Therapeutics filed an 8-K on Mar 30, 2026 that reports results of operations and provides updated financial statements and exhibits, a filing investors should note for transparency around the company's recent operating performance.

The 8-K carries accession number 0001193125-26-130480 and a reported file size of 426 KB. While the filing itself does not include headline financial metrics in the summary, it formally updates the company's disclosure record with the SEC.

What's Happening

The company's Form 8-K documents two principal items that affect how investors and analysts track Tempest's financial position and reporting status.

• Filed Date: 2026-03-30, indicating the disclosure was submitted to the SEC on Mar 30, 2026. This updates the public record for the company as of that date.
• Accession Number: 0001193125-26-130480, the unique SEC identifier for this filing that you can use to locate the full 8-K on EDGAR.
• CIK / Filer: 0001544227, the company's Central Index Key on SEC records, confirming the filing is for Tempest Therapeutics, Inc.
• File Size: 426 KB, which indicates the filing includes substantive attachments such as financial statements or exhibits rather than a brief notice.
• Item 2.02: Results of Operations and Financial Condition, meaning the 8-K conveys operational results or changes in financial condition that the company considered material enough to report outside its periodic filings.
• Item 9.01: Financial Statements and Exhibits, which confirms the 8-K includes or references financial statements and supporting exhibits filed with the disclosure.

Each of these elements matters because they change what’s available in the public record. The inclusion of Item 2.02 signals management has provided management-level commentary or figures tied to operating results, and Item 9.01 means you can expect detailed exhibits or statements to review.

Why It Matters For Your Portfolio

An 8-K that reports results of operations and attaches financial statements affects transparency and the information set investors use to value a company. For shareholders and potential buyers, updated filings can clarify recent cash position, revenue recognition, or expense items that influence near-term runway and strategic options.

Different investors will interpret this filing differently. Short-term traders may react to any newly disclosed figures or language that signal momentum or deterioration. Long-term investors will want to read the attached statements to assess trends in cash burn and operating results. Income-focused investors are unlikely to be affected directly unless the filing addresses dividends or capital allocation, which this particular 8-K does not explicitly state.

Risks To Consider

• Limited detail in the 8-K summary, which means initial headlines may not capture the full financial picture until you review the exhibits and statements.
• Potential for material revisions, if the detailed statements reveal weaker operating results, higher expenses, or cash constraints that could pressure the company.
• Biotech or development-stage company sensitivity, where results of operations can fluctuate significantly and regulatory or clinical outcomes may materially change the outlook.

What To Watch Next

You should follow the SEC filing itself and the company's subsequent communications closely. Key next steps and signals to monitor include:

• Read the full 8-K and attached exhibits via accession number 0001193125-26-130480 to see the detailed financial statements and any management discussion.
• Look for follow-up filings, such as a Form 10-Q or Form 10-K amendments, that may expand on the figures or provide reconciliations.
• Monitor press releases or investor presentations from the company that could summarize the operational results in plain language and explain near-term plans.
• Track any material changes in liquidity metrics or footnote disclosures in the exhibits that could affect runway or financing needs.

The Bottom Line

• Tempest Therapeutics filed an 8-K on Mar 30, 2026 reporting results of operations and including financial statements and exhibits, updating the SEC record under accession number 0001193125-26-130480.
• Investors should review the attached exhibits to understand any changes in revenue, expenses, cash position, or contingencies rather than relying on summary headlines.
• If you own shares or are tracking the company, prioritize the detailed statements for implications on runway and near-term financing needs.
• Watch for follow-up SEC filings and company releases that provide context or management commentary to the raw financial data.
• Use the filing as a prompt to reassess risk exposure, especially if the detailed exhibits reveal operational or liquidity pressures.

FAQ

Q: What did the 8-K filed by Tempest Therapeutics disclose?

A: The 8-K, filed Mar 30, 2026 with accession number 0001193125-26-130480, reports results of operations and includes financial statements and exhibits under Items 2.02 and 9.01.

Q: Where can I find the full filing and exhibits?

A: You can access the filing on the SEC EDGAR database using the accession number 0001193125-26-130480 or the company's CIK 0001544227 to retrieve the full 8-K and attachments.

Q: How should I use this information in my investment review?

A: Review the attached financial statements and exhibits to assess cash position, operating results, and any new disclosures. Those details will inform your view of the company’s short-term liquidity and operational trajectory.